Cid Ruzafa J, Paczkowski R, Boye K S, Di Tanna G L, Sheetz M J, Donaldson R, Breyer M D, Neasham D, Voelker J R
Evidera, London, UK.
Eli Lilly and Company, Indianapolis, IN, USA.
Int J Clin Pract. 2015 Aug;69(8):871-82. doi: 10.1111/ijcp.12640. Epub 2015 May 25.
To examine the rates of diabetic kidney disease (DKD) progression and associated factors, we undertook a study of estimated glomerular filtration rate (eGFR) in a historical cohort of UK primary care patients with type 2 diabetes mellitus (T2DM) and associated DKD from the Clinical Practice Research Datalink.
Our eligible population were patients with definitive T2DM from a recorded diagnostic code with either a diagnosis of chronic kidney disease (CKD) or renal function test values and renal abnormalities consistent with a CKD diagnosis, identified between 1 October 2006 and 31 December 2011. Only patients with albuminuria results reported in mg/l were used for the longitudinal statistical analyses of the eGFR rate of change using multilevel models.
We identified 111,030 patients with T2DM. Among them 58.6% (95% confidence interval (CI): 58.3-58.9) had CKD and 37.2% (95% CI: 36.9-37.5%) had presumed DKD at baseline. Only 19.4% of patients had urinary albumin test results expressed as mg/l in the year prior to index date. Almost two-thirds (63.8%) of patients with T2DM and presumed DKD received prescriptions for angiotensin-converting enzyme (ACE) inhibitors or angiotensin type 1 receptor blockers (ARB) or both. Time-dependent variables that predict subsequent eGFR decline include increased albuminuria, time from index date and older age.
Only a minority of diabetic patients with DKD had quantitative albuminuria assessments. The relatively low proportion of DKD patients with ACEi or ARB prescriptions suggests a gap between healthcare practice and available scientific evidence during the study period. Increased albuminuria and older age were the most consistent predictors of subsequent eGFR decline.
为了研究糖尿病肾病(DKD)的进展率及相关因素,我们对英国临床实践研究数据链中2型糖尿病(T2DM)及相关DKD的初级保健患者历史队列的估算肾小球滤过率(eGFR)进行了一项研究。
我们符合条件的人群是2006年10月1日至2011年12月31日期间通过记录诊断代码确诊为T2DM且诊断为慢性肾脏病(CKD)或肾功能测试值及肾脏异常符合CKD诊断的患者。仅使用以mg/l报告的蛋白尿结果的患者,通过多水平模型对eGFR变化率进行纵向统计分析。
我们识别出111,030例T2DM患者。其中58.6%(95%置信区间(CI):58.3 - 58.9)在基线时有CKD,37.2%(95% CI:36.9 - 37.5%)在基线时有疑似DKD。在索引日期前一年,仅有19.4%的患者有以mg/l表示的尿白蛋白检测结果。几乎三分之二(63.8%)的T2DM及疑似DKD患者接受了血管紧张素转换酶(ACE)抑制剂或1型血管紧张素受体阻滞剂(ARB)或两者的处方。预测随后eGFR下降的时间依赖性变量包括蛋白尿增加、距索引日期的时间和年龄较大。
仅有少数DKD糖尿病患者进行了定量蛋白尿评估。DKD患者中接受ACEi或ARB处方的比例相对较低,这表明在研究期间医疗实践与现有科学证据之间存在差距。蛋白尿增加和年龄较大是随后eGFR下降最一致的预测因素。